;PMID: 9560119
;source_file_1404.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..34] = [t:0..34]
;1)sentence:[e:39..108] = [t:39..108]
;2)section:[e:112..168] = [t:112..168]
;3)section:[e:172..260] = [t:172..260]
;4)sentence:[e:264..275] = [t:264..275]
;5)sentence:[e:276..376] = [t:276..376]
;6)sentence:[e:377..481] = [t:377..481]
;7)sentence:[e:482..503] = [t:482..503]
;8)sentence:[e:505..667] = [t:505..667]
;9)sentence:[e:668..676] = [t:668..676]
;10)sentence:[e:677..801] = [t:677..801]
;11)sentence:[e:802..957] = [t:802..957]
;12)sentence:[e:958..1171] = [t:958..1171]
;13)sentence:[e:1172..1184] = [t:1172..1184]
;14)sentence:[e:1185..1366] = [t:1185..1366]
;15)section:[e:1370..1414] = [t:1370..1414]

;section 0 Span:0..34
;Am J Surg  1998 Mar;175(3):198-202
(SEC
  (FRAG (NNP:[0..2] Am) (NNP:[3..4] J) (NNP:[5..9] Surg) (CD:[11..15] 1998)
        (CD:[16..24] Mar;175-LRB-) (CD:[24..25] 3) (-RRB-:[25..26] -RRB-)
        (CD:[26..30] :198) (HYPH:[30..31] -) (CD:[31..34] 202)))

;sentence 1 Span:39..108
;The type of K-ras mutation determines prognosis in colorectal cancer.
;[51..56]:gene-rna:"K-ras"
;[90..107]:malignancy:"colorectal cancer"
(SENT
  (S-HLN
    (NP-SBJ
      (NP (DT:[39..42] The) (NN:[43..47] type))
      (PP (IN:[48..50] of)
        (NP (NN:[51..56] K-ras) (NN:[57..65] mutation))))
    (VP (VBZ:[66..76] determines)
      (NP (NN:[77..86] prognosis))
      (PP (IN:[87..89] in)
        (NP (JJ:[90..100] colorectal) (NN:[101..107] cancer))))
    (.:[107..108] .)))

;section 2 Span:112..168
;Cerottini JP, Caplin S, Saraga E, Givel JC, Benhattar J.
(SEC
  (FRAG (NNP:[112..121] Cerottini) (NNP:[122..124] JP) (,:[124..125] ,)
        (NNP:[126..132] Caplin) (NNP:[133..135] S,) (NNP:[136..142] Saraga)
        (NNP:[143..144] E) (,:[144..145] ,) (NNP:[146..151] Givel)
        (NNP:[152..154] JC) (,:[154..155] ,) (NNP:[156..165] Benhattar)
        (NNP:[166..168] J.)))

;section 3 Span:172..260
;Department of Surgery, Centre Hospitalier Universitaire Vaudois, Lausanne, 
;Switzerland.
(SEC
  (FRAG (NNP:[172..182] Department) (IN:[183..185] of) (NNP:[186..193] Surgery)
        (,:[193..194] ,) (NNP:[195..201] Centre) (NNP:[202..213] Hospitalier)
        (NNP:[214..227] Universitaire) (NNP:[228..235] Vaudois) (,:[235..236] ,)
        (NNP:[237..245] Lausanne) (,:[245..246] ,) (NNP:[248..259] Switzerland)
        (.:[259..260] .)))

;sentence 4 Span:264..275
;BACKGROUND:
(SENT
  (NP (NN:[264..274] BACKGROUND) (::[274..275] :)))

;sentence 5 Span:276..376
;Mutations involving the oncogene K-ras in colorectal cancer may be  related
;to tumor aggressiveness.
;[309..314]:gene-rna:"K-ras"
;[318..335]:malignancy:"colorectal cancer"
(SENT
  (S
    (NP-SBJ-1
      (NP (NNS:[276..285] Mutations))
      (VP (VBG:[286..295] involving)
        (NP
          (NP (DT:[296..299] the) (NN:[300..308] oncogene))
          (NP (NN:[309..314] K-ras)))
        (PP (IN:[315..317] in)
          (NP (JJ:[318..328] colorectal) (NN:[329..335] cancer)))))
    (VP (MD:[336..339] may)
      (VP (VB:[340..342] be)
        (VP (VBN:[344..351] related)
          (NP-1 (-NONE-:[351..351] *))
          (PP-CLR (TO:[352..354] to)
            (NP (NN:[355..360] tumor) (NN:[361..375] aggressiveness))))))
    (.:[375..376] .)))

;sentence 6 Span:377..481
;However, the value of K-ras gene determination  as a prognostic marker has
;not been clearly established.
;[399..404]:gene-rna:"K-ras"
(SENT
  (S
    (ADVP (RB:[377..384] However))
    (,:[384..385] ,)
    (NP-SBJ-1
      (NP (DT:[386..389] the) (NN:[390..395] value))
      (PP (IN:[396..398] of)
        (NP (NN:[399..404] K-ras) (NN:[405..409] gene)
            (NN:[410..423] determination)))
      (PP (IN:[425..427] as)
        (NP (DT:[428..429] a) (JJ:[430..440] prognostic) (NN:[441..447] marker))))
    (VP (VBZ:[448..451] has) (RB:[452..455] not)
      (VP (VBN:[456..460] been)
        (ADVP (RB:[461..468] clearly))
        (VP (VBN:[469..480] established)
          (NP-1 (-NONE-:[480..480] *)))))
    (.:[480..481] .)))

;sentence 7 Span:482..503
;PATIENTS AND METHODS:
(SENT
  (NP (NNS:[482..490] PATIENTS) (CC:[491..494] AND) (NNS:[495..502] METHODS)
      (::[502..503] :)))

;sentence 8 Span:505..667
;The results from 98 patients recruited in a prospective study analyzing the 
;effect of a K-ras mutation as a prognostic factor in colorectal cancer are 
;reported.
;[594..599]:gene-rna:"K-ras"
;[635..652]:malignancy:"colorectal cancer"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[505..508] The) (NNS:[509..516] results))
      (PP (IN:[517..521] from)
        (NP
          (NP (CD:[522..524] 98) (NNS:[525..533] patients))
          (VP (VBN:[534..543] recruited)
            (NP (-NONE-:[543..543] *))
            (PP (IN:[544..546] in)
              (NP
                (NP (DT:[547..548] a) (JJ:[549..560] prospective)
                    (NN:[561..566] study))
                (VP (VBG:[567..576] analyzing)
                  (NP
                    (NP (DT:[577..580] the) (NN:[582..588] effect))
                    (PP (IN:[589..591] of)
                      (NP (DT:[592..593] a) (NN:[594..599] K-ras)
                          (NN:[600..608] mutation)))
                    (PP (IN:[609..611] as)
                      (NP (DT:[612..613] a) (JJ:[614..624] prognostic)
                          (NN:[625..631] factor)))
                    (PP (IN:[632..634] in)
                      (NP (JJ:[635..645] colorectal) (NN:[646..652] cancer)))))))))))
    (VP (VBP:[653..656] are)
      (VP (VBN:[658..666] reported)
        (NP-1 (-NONE-:[666..666] *))))
    (.:[666..667] .)))

;sentence 9 Span:668..676
;RESULTS:
(SENT
  (NP (NNS:[668..675] RESULTS) (::[675..676] :)))

;sentence 10 Span:677..801
;Disease-free (P = 0.02) and overall survival (P = 0.03) were  significantly
;reduced for patients harboring a K-ras mutation.
;[786..791]:gene-rna:"K-ras"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[677..684] Disease) (HYPH:[684..685] -) (JJ:[685..689] free)
        (PRN (-LRB-:[690..691] -LRB-)
          (S
            (NP-SBJ (NN:[691..692] P))
            (VP (SYM:[693..694] =)
              (NP (CD:[695..699] 0.02))))
          (-RRB-:[699..700] -RRB-)))
      (CC:[701..704] and)
      (NP (JJ:[705..712] overall) (NN:[713..721] survival)
        (PRN (-LRB-:[722..723] -LRB-)
          (S
            (NP-SBJ (NN:[723..724] P))
            (VP (SYM:[725..726] =)
              (NP (CD:[727..731] 0.03))))
          (-RRB-:[731..732] -RRB-))))
    (VP (VBD:[733..737] were)
      (ADVP (RB:[739..752] significantly))
      (VP (VBN:[753..760] reduced)
        (NP-1 (-NONE-:[760..760] *))
        (PP (IN:[761..764] for)
          (NP
            (NP (NNS:[765..773] patients))
            (VP (VBG:[774..783] harboring)
              (NP (DT:[784..785] a) (NN:[786..791] K-ras)
                  (NN:[792..800] mutation)))))))
    (.:[800..801] .)))

;sentence 11 Span:802..957
;Two specific  mutations demonstrated a significantly increased risk of
;disease recurrence,  namely, 12-TGT (P = 0.04) and 13-GAC substitutions (P =
;0.002).
;[816..825]:variation-event:"mutations"
;[902..904]:variation-location:"12"
;[905..908]:variation-state-generic:"TGT"
;[924..926]:variation-location:"13"
;[927..930]:variation-state-generic:"GAC"
;[931..944]:variation-type:"substitutions"
(SENT
  (S
    (NP-SBJ
      (NP (CD:[802..805] Two) (JJ:[806..814] specific)
          (NNS:[816..825] mutations))
      (NP-2 (-NONE-:[825..825] *ICH*)))
    (VP (VBD:[826..838] demonstrated)
      (NP
        (NP (DT:[839..840] a)
          (ADJP (RB:[841..854] significantly) (VBN:[855..864] increased))
          (NN:[865..869] risk))
        (PP (IN:[870..872] of)
          (NP (NN:[873..880] disease) (NN:[881..891] recurrence))))
      (,:[891..892] ,)
      (NP-2
        (ADVP (RB:[894..900] namely))
        (,:[900..901] ,)
        (NP
          (NML (CD:[902..904] 12) (HYPH:[904..905] -) (NN:[905..908] TGT))
          (NML-1 (-NONE-:[908..908] *P*))
          (PRN (-LRB-:[909..910] -LRB-)
            (S
              (NP-SBJ (NN:[910..911] P))
              (VP (SYM:[912..913] =)
                (NP (CD:[914..918] 0.04))))
            (-RRB-:[918..919] -RRB-)))
        (CC:[920..923] and)
        (NP
          (NML (CD:[924..926] 13) (HYPH:[926..927] -) (NN:[927..930] GAC))
          (NML-1 (NNS:[931..944] substitutions))
          (PRN (-LRB-:[945..946] -LRB-)
            (S
              (NP-SBJ (NN:[946..947] P))
              (VP (SYM:[948..949] =)
                (NP (CD:[950..955] 0.002))))
            (-RRB-:[955..956] -RRB-)))))
    (.:[956..957] .)))

;sentence 12 Span:958..1171
;Patients with  either of these substitutions had a 2-year disease-free
;survival rate of 37%  compared with that of 67% for the group of patients
;harboring any other mutation  type or a wild-type status (P = 0.01).
;[989..1002]:variation-type:"substitutions"
;[1123..1131]:variation-event:"mutation"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[958..966] Patients))
      (PP (IN:[967..971] with)
        (NP
          (NP (DT:[973..979] either))
          (PP (IN:[980..982] of)
            (NP (DT:[983..988] these) (NNS:[989..1002] substitutions))))))
    (VP (VBD:[1003..1006] had)
      (NP
        (NP (DT:[1007..1008] a)
          (NML
            (NML (CD:[1009..1010] 2) (HYPH:[1010..1011] -)
                 (NN:[1011..1015] year))
            (NN:[1016..1023] disease) (HYPH:[1023..1024] -)
             (JJ:[1024..1028] free))
          (NN:[1029..1037] survival) (NN:[1038..1042] rate))
        (PP (IN:[1043..1045] of)
          (NP (CD:[1046..1048] 37) (NN:[1048..1049] %))))
      (S-ADV
        (NP-SBJ-1 (-NONE-:[1049..1049] *))
        (VP (VBN:[1051..1059] compared)
          (NP-1 (-NONE-:[1059..1059] *))
          (PP-CLR (IN:[1060..1064] with)
            (NP
              (NP (DT:[1065..1069] that))
              (PP (IN:[1070..1072] of)
                (NP (CD:[1073..1075] 67) (NN:[1075..1076] %)))
              (PP (IN:[1077..1080] for)
                (NP
                  (NP
                    (NP (DT:[1081..1084] the) (NN:[1085..1090] group))
                    (PP (IN:[1091..1093] of)
                      (NP (NNS:[1094..1102] patients))))
                  (VP (VBG:[1103..1112] harboring)
                    (NP
                      (NP (DT:[1113..1116] any) (JJ:[1117..1122] other)
                          (NN:[1123..1131] mutation) (NN:[1133..1137] type))
                      (CC:[1138..1140] or)
                      (NP (DT:[1141..1142] a)
                        (NML (JJ:[1143..1147] wild) (HYPH:[1147..1148] -)
                             (NN:[1148..1152] type))
                        (NN:[1153..1159] status))))))))
          (PRN (-LRB-:[1160..1161] -LRB-)
            (S
              (NP-SBJ (NN:[1161..1162] P))
              (VP (SYM:[1163..1164] =)
                (NP (CD:[1165..1169] 0.01))))
            (-RRB-:[1169..1170] -RRB-)))))
    (.:[1170..1171] .)))

;sentence 13 Span:1172..1184
;CONCLUSIONS:
(SENT
  (NP (NNS:[1172..1183] CONCLUSIONS) (::[1183..1184] :)))

;sentence 14 Span:1185..1366
;The results herein presented  suggest that K-ras acts as a prognostic factor
;in colorectal cancer and that  this effect is probably related to a limited
;number of defined mutations.
;[1228..1233]:gene-rna:"K-ras"
;[1265..1282]:malignancy:"colorectal cancer"
;[1356..1365]:variation-event:"mutations"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1185..1188] The) (NNS:[1189..1196] results))
      (VP
        (ADVP (RB:[1197..1203] herein))
        (VBN:[1204..1213] presented)
        (NP (-NONE-:[1213..1213] *))))
    (VP (VBP:[1215..1222] suggest)
      (SBAR
        (SBAR (IN:[1223..1227] that)
          (S
            (NP-SBJ (NN:[1228..1233] K-ras))
            (VP (VBZ:[1234..1238] acts)
              (PP (IN:[1239..1241] as)
                (NP (DT:[1242..1243] a) (JJ:[1244..1254] prognostic)
                    (NN:[1255..1261] factor)))
              (PP (IN:[1262..1264] in)
                (NP (JJ:[1265..1275] colorectal) (NN:[1276..1282] cancer))))))
        (CC:[1283..1286] and)
        (SBAR (IN:[1287..1291] that)
          (S
            (NP-SBJ-1 (DT:[1293..1297] this) (NN:[1298..1304] effect))
            (VP (VBZ:[1305..1307] is)
              (ADVP (RB:[1308..1316] probably))
              (VP (VBN:[1317..1324] related)
                (NP-1 (-NONE-:[1324..1324] *))
                (PP-CLR (TO:[1325..1327] to)
                  (NP
                    (NP (DT:[1328..1329] a) (VBN:[1330..1337] limited)
                        (NN:[1338..1344] number))
                    (PP (IN:[1345..1347] of)
                      (NP (VBN:[1348..1355] defined)
                          (NNS:[1356..1365] mutations)))))))))))
    (.:[1365..1366] .)))

;section 15 Span:1370..1414
;PMID: 9560119 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1370..1374] PMID) (::[1374..1375] :) (CD:[1376..1383] 9560119)
        (IN:[1384..1385] -LSB-) (NNP:[1385..1391] PubMed) (HYPH:[1392..1393] -)
        (JJ:[1394..1401] indexed) (IN:[1402..1405] for)
        (NNP:[1406..1414] MEDLINE-RSB-)))
